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Background: The bumetanide (BMT)-sensitive Na+-K+-2Cl− cotransporter isoform 1 (NKCC1) maintains cell volume
homeostasis by increasing intracellular K+ and Cl− content via regulatory volume increase (RVI). Expression levels of
NKCC1 positively correlate with the histological grade and severity of gliomas, the most common primary adult
brain tumors, and up-regulated NKCC1 activity facilitates glioma cell migration and apoptotic resistance to the
chemotherapeutic drug temozolomide (TMZ). However, the cellular mechanisms underlying NKCC1 functional
up-regulation in glioma and in response to TMZ administration remain unknown.
Methods: Expression of NKCC1 and its upstream kinases With-No-K (Lysine) kinase 1 (WNK1) and oxidative
stress-responsive kinase-1 (OSR1) in different human glioma cell lines and glioma specimens were detected by
western blotting and immunostaining. Live cell imaging and microchemotaxis assay were applied to record glioma
cell movements under different treatment conditions. Fluorescence indicators were utilized to measure cell volume,
intracellular K+ and Cl− content to reflect the activity of NKCC1 on ion transportation. Small interfering RNA
(siRNA)-mediated knockdown of WNK1 or OSR1 was used to explore their roles in regulation of NKCC1 activity in
glioma cells. Results of different treatment groups were compared by one-way ANOVA using the Bonferroni
post-hoc test in the case of multiple comparisons.
Results: We show that compared to human neural stem cells and astrocytes, human glioma cells exhibit robust
increases in the activation and phosphorylation of NKCC1 and its two upstream regulatory kinases, WNK1 and OSR1.
siRNA-mediated knockdown of WNK1 or OSR1 reduces intracellular K+ and Cl− content and RVI in glioma cells by
abolishing NKCC1 regulatory phospho-activation. Unexpectedly, TMZ activates the WNK1/OSR1/NKCC1 signaling
pathway and enhances glioma migration. Pharmacological inhibition of NKCC1 with its potent inhibitor BMT or
siRNA knockdown of WNK1 or OSR1 significantly decreases glioma cell migration after TMZ treatment.
Conclusion: Together, our data show a novel role for the WNK1/OSR1/NKCC1 pathway in basal and TMZ-induced
glioma migration, and suggest that glioma treatment with TMZ might be improved by drugs that inhibit elements
of the WNK1/OSR1/NKCC1 signaling pathway.
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Glioblastoma multiforme (GBM) is the most common
malignant primary brain tumor in adults. The standard
treatment of malignant glioma includes maximal surgical
resection followed by concurrent radiation and chemo-
therapy with temozolomide (TMZ) [1]. Despite aggressive
treatment, GBM patients have a poor median survival of
14 months [2]. The highly infiltrative behavior of gliomas
causes difficulties in achieving complete surgical resec-
tions. Recurrence of the disease is attributed in part to re-
sistance of glioma cells to the standard chemotherapeutic
reagent TMZ [3]. It is important to identify new thera-
peutic targets to hinder the migration of the invasive
glioma cells and sensitize glioma cells to chemotherapy.
Ion channels and ion transporters have emerged to
play an important role in tumorigenesis, glioma migra-
tion and metastasis [4]. Expression of Na+-K+-2Cl−
cotransporter isoform 1 (NKCC1) in human glioma has
been shown to positively correlate with the tumor
grades. NKCC1 is involved in glioma migration through
regulation of focal adhesion dynamics, cell contractility,
and cell volume [5-7]. Pharmacological inhibition or
shRNA-mediated knockdown of NKCC1 decreases gli-
oma cell migration and invasion [5,7]. Recently, we re-
ported that NKCC1 activity is important in GC survival
[8]. NKCC1 is the key ion transporter in regulation of
intracellular K+ (K+i ), Cl
− (Cl−i ) and cell volume in pri-
mary glioma cells (GCs) and glioma stem cells (GSCs)
[8]. Most importantly, TMZ stimulates NKCC1 activity
to counteract loss of K+i and Cl
−
i and apoptotic volume
decrease (AVD) during early apoptosis [8]. Inhibition of
NKCC1 activity with its potent inhibitor bumetanide
(BMT) enhanced TMZ-mediated apoptosis in both GCs
and GSCs [8]. However, the mechanisms underlying
NKCC1 up-regulation in glioma, and how NKCC1 activ-
ity is modulated by TMZ, are unknown.
Activation of NKCC1 protein is regulated by a family of
kinases named the With-No-K (Lysine) kinases (WNKs,
WNK1-4) [9]. To date, the best characterized substrates of
WNKs include two mammalian protein kinases in the ger-
minal center kinase-VI subfamily, SPS1-related proline/
alanine-rich kinase (SPAK) and oxidative stress-responsive
kinase 1 (OSR1) [9]. In our previous study, we docu-
mented that TMZ treatment triggered increased phos-
phorylation of WNK1 in both GCs and GSCs [8]. But, it
has not yet been defined whether SPAK and/or OSR1 are
the intermediate regulatory kinases in modulating NKCC1
function in GCs.
In the present study, we investigated whether WNK1-
SPAK/OSR1 signaling pathway regulates NKCC1 activity
in GCs and whether this signaling pathway is involved in
regulation of glioma migration, with and without che-
motherapeutic treatment. We report here that WNK1
and OSR1 are the dominant upstream regulatory kinasesof NKCC1 in glioma cells. Moreover, the WNK1/OSR1/
NKCC1 signaling pathway plays an important role in gli-
oma migration and is stimulated by TMZ. These findings
illustrate significant potentials of this signal transduction
pathway as new therapeutic targets for combined chemo-
radiotherapy for GBM.Results
Abundant expression of WNK1/OSR1/NKCC1 proteins in
glioma cells
First, we characterized expression of WNK1, SPAK, OSR1,
and NKCC1 protein in human neural stem cells (NSC),
human astrocytes (HA), primary glioma cells (GC#99 and
GC#22), and GBM cell line U87. As shown in Figure 1A
and B, NSC and HA showed relative low expression of p-
NKCC1 and t-NKCC1. In contrast, all three glioma cell
lines exhibited abundant expression of both proteins. Nor-
malized by the expression level in NSC, p-NKCC1 protein
was 17.6 ± 3.1 folds higher in U87, 20.1 ± 1.2 folds higher
in GC#99, and 18.5 ± 1.7 folds in GC#22. The expression
of t-NKCC1 ranged from 7.9 ± 1.0 folds in U87 to 12.1 ±
2.7 folds in GC#99. Similar abundant expression of p-
WNK1 and t-WNK1 was also detected in GCs. p-WNK1
was 4 ~ 20 folds more abundant in GCs than in NSC and
t-WNK1 was 12.5 ~ 20 folds higher in GCs (Figure 1A
and B). In contrast, NSC expressed relatively higher level
of t-OSR1. GC#99 only contained 47.6 ± 9% of t-OSR1
(p < 0.05) and GC#22 had 31.4 ± 2% of t-OSR1, compared
to NSC (p < 0.05). Interestingly, the basal expression of
p-OSR1 remained high in both primary glioma cell lines
as well as in U87 (p < 0.05) (Figure 1A and B). Moreover,
expression of p-SPAK and t-SPAK was barely detectable in
all three glioma cell lines and in HA (Figure 1A and B).
The presence of trace p-SPAK and t-SPAK signals in
GC#99, GC#22 and U87 samples was revealed when
ECL exposure time was increased to 3 h (Additional file 1:
Figure S1).
Expression of NKCC1 and OSR1 protein was also de-
tected in GBM xenograft tissues in SCID mouse brains
derived from human GSC#22. As shown in Figure 1C,
almost all cells within the human GBM xenografts ex-
hibited positive immunostaining for p-NKCC1, and t-
NKCC1 (Figure 1C). Moreover, p-OSR1 was abundantly
expressed in GBM xenograft tissues or GBM tissue array
samples (Figure 1D and E). Normal brain samples exhib-
ited no or low level of p-OSR1 immunoreactive signals.
In contrast, ~50% of GBM biopsies showed moderate to
strong p-OSR1 expression (Figure 1F). Taken together,
we concluded that GCs express abundant p-WNK1,
p-OSR1 and p-NKCC1 proteins, but not SPAK protein.
In the rest of our study, we investigated regulation and
function of the WNK1/OSR1/NKCC1 signaling cascade
in GCs.
Figure 1 Abundant expression of WNK1/OSR1/NKCC1 in primary glioma cells and GBM tissues. A. Representative immunoblots for
expression of either phosphorylated (p-) or total (t-) NKCC1, WNK1, OSR1 and SPAK in human neural stem cell (NSC), human astrocyte (HA),
primary GC#99, GC#22 and U87. B. Summary data of immunoblotting. Upper and middle panels, expression of each protein was first normalized
by α-tubulin and relative expression level in each cell type was then normalized to NSC. Lower panel, expression of each phosphorylated protein
was first normalized by its total protein and relative expression level in each cell type was then normalized to NSC. Data are mean ± SEM. n = 3,
*p < 0.05 vs. NSC. C. Representative immunofluorescent staining of p-NKCC1, t-NKCC1 in xenograft brain tissues of SCID mouse derived from
glioma stem cell (GSC#22). Arrow, representative cells with positive staining of protein of interest. Insets: images with higher magnification.
D. Representative immunostaining of p-OSR1, t-OSR1 in xenograft brain tissues of SCID mouse derived from glioma stem cell (GSC#22). White box
in whole-brain images indicates the corresponding location of acquisition for high magnification photomicrographs. Arrow, representative cells
with positive staining of protein of interest. Insets: negative controls with primary antibodies omitted. E. Representative images of p-OSR1
immunohistochemistry with different p-OSR1 immunohistochemistry staining intensity in a tissue microarray (TMA) of GBM. Arrow, representative
cells with positive staining of protein of interest. F. Summary data of percentage of patients observed with different p-OSR1 expression scores
with either normal or GBM group.
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presence of TMZ treatment
Random cell movements were recorded with time-lapse
imaging technique. In the current study, TMZ at a con-
centration of 100 μM was chosen because it is similar tothe serum level of ~ 100 μM during clinical TMZ treat-
ment [10] and has been characterized in our previous
study [8]. Figure 2A illustrated individual glioma cell
moving traces in 5 h under different conditions (Con,
10 μM BMT, 100 μM TMZ, or 100 μM TMZ plus
Figure 2 Inhibition of NKCC1 activity abolishes glioma motility and serum-induced microchemotaxis in response to TMZ.
A. Representative images of cell random movment in the presence of control medium (DMEM + 10 % FBS) (Con), 10 μM BMT (BMT), 100 μM TMZ
(TMZ), or 100 μM TMZ plus 10 μM BMT (T + B) for 5 h. Three moving cells in the field were marked (#1-3). Yellow dashed line: changes of traces
of cell gravity center with in 5 h. B. Motility of glioma cells was recorded using the Nikon TiE time-lapse imaging system. Random moving traces
of 10 representative cells were shown under Con, BMT, TMZ, or T + B conditions in the 300-min recording period. C. Summary data of GC motility.
Accumulated distance of GC cell movement during 0–300 min was calculated in each condition. Data were mean ± SEM (n =4). *p < 0.05 vs. Con.
#p < 0.05 vs. TMZ. D. Summary data of average speed of GC movement in 5 h. Data were mean ± SEM (n =4). *p < 0.05 vs. Con. #p < 0.05 vs. TMZ.
E. Serum-induced microchemotaxis of GC#99 and GC#22 was determined using the Boyden Chamber (8 μm pore) for 5 h under different
treatment conditions (Con, BMT, TMZ, or TMZ plus BMT). Summary data of numbers of migrated cells per field in different treatment groups.
Data are mean ± SEM. n = 6, *p < 0.05 vs. Con. #p < 0.05 vs. TMZ.
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during the 5-h period (dashed lines). Figure 2B further
illustrates the random moving traces of GCs, showing
that the motility of GC#99 was clearly inhibited whenNKCC1 activity was blocked with BMT under either
control conditions or in the presence of TMZ. Moreover,
the motility of GC#22 appeared to be increased in the
presence of TMZ, but, this stimulation was attenuated
Figure 3 TMZ treatment activates the WNK1/OSR1/NKCC1 signaling pathway in GC#99 and GC#22. A and C. Representative immunoblots
showing increased expression of p-WNK1, p-OSR1 and p-NKCC1 proteins in response to TMZ exposure in GC#99 and GC#22. GCs were exposed
to control medium (Con), 10 μM bumetanide (BMT), 100 μM TMZ, or 100 μM TMZ plus 10 μM BMT (T + B) for 4 h. B and D. Summary data of
immunoblotting. Expression of each phosphorylated protein was first normalized by its total protein, and relative expression levels with different
treatments were then normalized to Con. Data are mean ± SEM. n = 4–5, *p < 0.05 vs. Con.
Zhu et al. Molecular Cancer 2014, 13:31 Page 5 of 15
http://www.molecular-cancer.com/content/13/1/31by inhibiting NKCC1 with BMT treatment. The summa-
rized data in Figure 2C illustrated that BMT significantly
reduced the basal level of GC#99 mobility by 56% under
control conditions (70.2 ± 4.8 μm vs 33.3 ± 2.4 μm travel
distance, p < 0.05). Moreover, BMT also suppressed the
GC#99 motility under TMZ-treated conditions (46.3 ±
2.8 μm, p < 0.05) (Figure 2D). On the other hand, GC#22
exhibited a low basal motility under control conditions
(travel distance of 35.23 ± 4.80 μm in 5 h). BMT treat-
ment had no effects on the basal motility (neither on the
total travel distance nor the speed, Figure 2C and D).
Interestingly, in the presence of TMZ, GC#22 cell mo-
bility was increased by 216 ± 9.1% of control (77.7 ±
8.0 μm in 5 h, p < 0.05). The mobility rate was doubled
from 1.17 to 2.59 μm/min. Most importantly, inhibition
of NKCC1 activity with BMT abolished this stimulation
in GC#22 (p < 0.05, Figure 2C and D).
To further validate these phenomena, we examined
migration behaviors of GC#99 and GC#22 in the
serum-induced microchemotaxis assay. Consistent with
their motility profiles with live cell imaging, GC#99 ex-
hibited a higher basal cell migration level (29.1 ± 2.1cells/field, Figure 2E). BMT decreased GC#99 migration
by 56.3 ± 7.4% (p < 0.05). TMZ treatment did not change
the migration rate of GC#99, but BMT remains effective
in reducing GC#99 migration in the presence of TMZ
(Figure 2E, left panel). In contrast, GC#22 exhibited
lower basal migratory ability through the 8-μm trans-
well membrane under control conditions (12.8 ± 1.8
cells/field, Figure 2E, right panel). Inhibition of NKCC1
had no effects on the basal level of GC#22 migration.
However, the number of migrated cells of GC#22 sig-
nificantly increased in the presence of TMZ (29.2 ± 2.5
cells/field, p < 0.05). Inhibition of NKCC1 with BMT
treatment significantly attenuated the TMZ-mediated
stimulation of GC#22 migration (p < 0.05, Figure 2E,
right panel). The commercial GBM cell line U87 exhib-
ited similar migratory pattern as GC#22 (Additional file 1:
Figure S2). Taken together, these studies revealed that
GC#99 and GC#22 exhibited heterogeneity in basal mo-
bility, migration and sensitivity to NKCC1 inhibition and
TMZ treatments. These findings led us to further investi-
gate how NKCC1 protein is regulated in GC#99 and
GC#22 in response to TMZ treatment.
Figure 4 siRNA-mediated down-regulation of WNK1/OSR1 attenuates the TMZ-induced NKCC1 activation. A. Representative immunoblots
showing effects of WNK1 siRNA treatment on expression of t-WNK1 (upper panel) and p-NKCC1, p-OSR1 and p-SPAK (lower panel).
C. Representative immunoblots showing effects of OSR1 siRNA treatment on expression of t-OSR1 (upper panel) and p-NKCC1 (lower panel).
GC#99 were treated with either scramble siRNA (Scr), WNK1 siRNA, or OSR1 siRNA for 48 h, followed by exposure to control medium (Con),
10 μM BMT, 100 μM TMZ, or 100 μM TMZ plus 10 μM BMT (T + B) for 4 h. B and D. Summary data of immunoblotting. Left panel, the expression
level of each phosphorylated protein was normalized by its total protein and then the basal expression under control conditions. Right panel, the
expression level of each total protein was normalized by α-tubulin and then the basal expression in Scr-treated cells under control conditions.
Data are mean ± SEM, n = 3 ~ 5, *p < 0.05 vs. Con, #p < 0.05 vs. Scr.
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transduction pathway in GCs
In order to understand how NKCC1 protein is regulated
in GC#99 and GC#22 in response to TMZ, we first exam-
ined whether TMZ stimulates the WNK1/OSR1 signaling
pathway in GCs. As shown in Figure 3A, exposing GC#99
to TMZ for 4 h triggered an increase of p-NKCC1 expres-
sion and a concurrent change of the upstream kinases p-
WNK1 and p-OSR1. Figure 3B shows that p-WNK1 was
increased by 176.7 ± 20.6% of control (p < 0.05), p-OSR1
by 199.2 ± 15.7% of control (p < 0.05), and p-NKCC1 by
171.9 ± 8.9% of control (p < 0.05) after TMZ treatment.
However, p-SPAK and the total protein level of each tested
protein in GC#99 were not significantly altered by TMZ
(Figure 3A, B and Additional file 1: Figure S3). Moreover,
the combined treatment of TMZ and BMT did not affect
the TMZ-induced up-regulation of p-WNK1, p-OSR1 or
p-NKCC1 in GC#99.
In the case of GC#22, TMZ triggered similar activation
patterns of the WNK1/OSR1/NKCC1 cascade. The p-
WNK1 expression was increased by 169.1 ± 18.6% of con-
trol (p < 0.05) and p-OSR1 was elevated by 170.0 ± 12.4%
of control (p < 0.05) and p-NKCC1 was by 189.4 ± 8.4% ofcontrol (p < 0.05, Figure 3C and D). Moreover, t-WNK1, t-
OSR1, t-NKCC1 and t-SPAK remained unchanged in both
TMZ-treated and TMZ+ BMT-treated cells (Additional
file 1: Figure S3). Last, BMT treatment did not affect
the TMZ-mediated elevation of p-WNK1, p-OSR1 or p-
NKCC1 in GC#22. No changes of p-SPAK were observed
in the TMZ-treated GC#22. In summary, TMZ triggered
activation of the WNK1/OSR1/NKCC1 signaling pathway
in both GC#99 and GC#22, while SPAK protein was not
activated and likely plays a minimal role in these cells.
Down-regulation of the WNK1/OSR1 pathway abolishes
the TMZ-induced NKCC1 activation
To further determine that WNK1 and OSR1 are the up-
stream kinases regulating NKCC1 activity in GCs, siRNA
knockdown approach was used to selectively reduce pro-
tein expression of either WNK1 or OSR1 in GC#99 cells.
Compared to scramble siRNA (Scr)-treated cells, expres-
sion of t-WNK1 in the WNK1 siRNA-treated cells was re-
duced by ~ 50% (48.3 ± 5.3% scr, p < 0.05, Figure 4A).
WNK1 siRNA treatment did not alter the expression levels
of t-NKCC1, t-OSR1 and t-SPAK. As expected, down-
regulation of WNK1 in GC#99 lowered the expression of
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T + B, Figure 4A). Most importantly, TMZ failed to induce
elevation of p-NKCC1 expression in the WNK1 siRNA-
treated GC#99 (95.2 ± 23.1% of Con WNK1 siRNA-
treated cells, Figure 4A and B). Moreover, down-regulation
of WNK1 in GC#99 also significantly attenuated the
TMZ-induced activation of OSR1 (124.8 ± 28.1% in WNK1
siRNA-treated cells vs. 202.4 ± 28.9% in the Scr-treated
cells) (Figure 4A and B). Expression of p-SPAK was
not significantly changed in either Scr-siRNA or WNK1
siRNA-treated cell. Taken together, these findings sug-
gest that WNK1 is the major WNK isoform regulating
NKCC1 in GC#99 and that WNK1 activation is re-
quired for the TMZ-mediated NKCC1 stimulation.
We then determined whether OSR1 is the intermedi-
ate player between WNK1 and NKCC1. After 48 h of
OSR1 siRNA treatment, t-OSR1 expression was reduced
by ~ 60% (57.2 ± 7.1% of Scr, p < 0.05), while t-NKCC1
expression was not affected (Figure 4C and D). TMZ
failed to stimulate p-NKCC1 expression in the OSR1
siRNA-treated GC#99 (p > 0.05, Figure 4C and D). These
data further suggest that OSR1 is downstream of WNK1
and collectively regulates NKCC1 activity in GCs.
Down-regulation of WNK1/OSR1 reduces
microchemotaxis of GCs
Given the important role of WNK1 and OSR1 in regula-
tion of NKCC1 in GCs, we further investigated whether
reduced expression of these upstream kinases will affect
the migratory behaviors of GCs, especially under TMZ
treatment. Figure 5A illustrated the representative im-
ages of GC#22 that migrated through the membrane in
the serum-induced microchemotaxis assay. Compared toFigure 5 siRNA-mediated down-regulation of WNK1/OSR1 reduces m
siRNA (Scr), WNK1 siRNA, or OSR1 siRNA, serum-induced microchemotaxis o
control medium (Con), 10 μM BMT, 100 μM TMZ, or 100 μM TMZ plus 10 μ
through an 8-μm transwell barrier after 5 h were shown. B. Summary data
groups. Data are mean ± SEM. n = 4, *p < 0.05 vs. Con. #p < 0.05 vs. Scr.Scr-treated cells, the number of migrated cells was
clearly less in the WNK1 siRNA-treated cells as well as
in the OSR1 siRNA-treated cells. Figure 5B is the sum-
marized data of the transwell-migration of both GC#22
and GC#99. In GC#22, reduced expression of WNK1
not only inhibited the TMZ-induced increase in migra-
tion (7.2 ± 1.2 cells/field vs. 17.1 ± 2.2 cells/field of Scr-
treated cells, p < 0.05), but also led to significant reduc-
tion in cell migration across other three conditions
(Con, BMT and T + B) (p < 0.05, Figure 5B, upper panel).
Similarly, TMZ failed to stimulate cell migration in the
OSR1-knockdown GC#22 (p < 0.05, Figure 5B, upper
panel). GC#99 exhibited similar results that knockdown
of either WNK1 or OSR1 protein expression signifi-
cantly decreased cell migration under both Con and
TMZ conditions (p < 0.05, Figure 5B, lower panel). But,
inhibition of NKCC1 with BMT had no further effects
on reducing GC#99 migration. Taken together, these
data strongly suggest that WNK1/OSR1/NKCC1 signal-
ing pathway plays an important role in regulation of
basal motility in GCs, and TMZ stimulates this signaling
pathway and promotes GC migration.
Down-regulation of WNK1 reduced [K+]i, [Cl
−]i, and
impaired cell volume regulation in GCs
We speculated that the WNK1/OSR1/NKCC1 signaling
pathway functions in regulation of GC migration via
changing K+i , and Cl
−
i ionic homeostasis and cell volume.
We examined whether knockdown of the WNK1 affects
GC ionic contents and cell volume regulation. As shown
in Figure 6A, exposing Scr-treated GC#99 cells to hyper-
tonic HEPES-MEM (367 mOsm) induced ~ 30 ± 4% cell
shrinkage in 3–5 min. This initial cell shrinkage isicrochemotaxis of GCs. A. After 48 h treatment with either scramble
f GC#22 was determined for 5 h under different treatment conditions
M BMT (T + B). Representative images of GC#22 that have migrated
of numbers of migrated GC#22 and GC#99 cells in different treatment
Figure 6 Inhibition of WNK1 abolishes NKCC1-mediated regulatory volume increase and K+i and Cl
−
i homeostasis. A. Cell water content
and relative cell volume were determined using the fluorescent dye calcein as described in Methods. GC#99 was treated with control medium,
scramble siRNA (Scr) or WNK1 siRNA for 48 h. To induce RVI, cells were exposed to isotonic HEPES-MEM (310 mOsm, 5 min), hypertonic
HEPES-MEM (370 mOsm, 25 min), and isotonic HEPES-MEM (5 min). The slope of the RVI was determined by fitting a regression line (in purple)
to the cell volume recovery at ~ 20–25 min after exposure to hypertonic stress. Right panel, summary data of RVI. Data are means ± SEM. n = 3–4.
B. Effects of WNK1 siRNA on [K+]i in GC#99. [K
+]i was determined using the fluorescent probe PBFI. Data are means ± SEM, n = 3. *p <0.05 vs. Scr.
C. Effects of WNK1 siRNA on [Cl−]i in GC#99. [Cl
−]i was determined using the fluorescent probe MQAE. Data are means ± SEM, n = 4. *p < 0.05 vs. Con;
#p < 0.05 vs. Scr + TMZ.
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started to recover cell volume by the process of RVI. Cell
volume started recovering at ~ 10–12 min at a rate of
0.05 ± 0.01% vol/min and nearly completely recovered by
25 min (a classical RVI response). In contrast, RVI re-
sponse was completely abolished in the WNK1 siRNA-
treated cells either in the absence or presence of TMZ
(Figure 6A, purple slope). We have previously shown
that RVI in glioma is largely mediated by the activity of
NKCC1 [8]. Therefore, in the WNK1 siRNA-treated
cells, NKCC1 activity was compromised and the cells
failed to recover the volume. The shrinkage response in
the WNK1 siRNA-treated cells appeared to be more
profound, which may be due to the additional activation
of outwardly directed K+-Cl− cotransporter and loss of
K+ and Cl− in response to down-regulation of WNK1, as
the WNK1-mediated phosphorylation of K+-Cl− cotran-
sporter inhibits its function [11].
Moreover, down-regulation of WNK1 also led to ~30 ±
2.9% loss of basal [K+]i (Figure 6B). TMZ did not cause
additional reduction in [K+]i ( ~35% loss of [K
+]i of con-
trols, Figure 6B). In contrast, TMZ treatment decreased
[Cl−]i by ~ 61% GC. Down regulation of WNK1 by
siRNA alone or combined with TMZ treatment further
lowered [Cl−]i by ~ 92% (Figure 6C). These results clearly
suggest that the upstream WNK1 kinase plays anessential role in maintaining [K+]i and [Cl
−]i as well as
cell volume regulation of GCs. Therefore, these func-
tions could involve in GC migration.NKCC1 phosphorylation and its interaction with ezrin,
radixin, and moesin protein complexes
ERM (Ezrin, Radixin, and Moesin) proteins play an im-
portant role in cancer migration and invasion and inter-
act with NKCC1 protein in glioma migration [5,12]. We
speculate that WNK1/OSR1-mediated phosphorylation
of NKCC1 protein may alter its interaction with ERM
complex and promote glioma cell migration. As shown in
Figure 7A, in GC#22 cells, p-NKCC1 protein in the im-
munoprecipitation fractions was significantly increased in
TMZ- or TMZ + BMT-treated group (Figure 7A). Interest-
ingly, ~ 4 fold increase in ezrin level was also detected in
the immunoprecipitation fractions of TMZ- or TMZ+
BMT-treated cells (p < 0.05, Figure 7A and B). Moreover,
p-ERM but not t-ERM was significantly increased in GCs
treated with TMZ or TMZ plus BMT (Figure 7B, p < 0.05).
Taken together, these findings suggest that there is an in-
creased interaction between p-NKCC1 and ezrin in GCs,
which may promote glioma cell migration in the presence
of TMZ. The phosphorylation of both NKCC1 and ERM
proteins may facilitate their interactions.
Figure 7 Interactions between NKCC1 and p-ERM in GCs. A. Representative immunoblots showing immunoprecipitation of ezrin, p-NKCC1,
or t-NKCC1 proteins in GCs. GC#22 cells were exposed to control medium (Con), 10 μM bumetanide (BMT), 100 μM TMZ, or 100 μM TMZ plus
10 μM BMT (T + B) for 4 h. B. Summary data of immunoblotting. Expression of each protein was first normalized by t-NKCC1. Relative expression
level under different treatments was normalized to Con. Data are mean ± SEM. n = 4, *p < 0.05 vs. Con. C. Representative immunoblots showing
expression of p-ERM and t-ERM proteins in GC#22. D. Summary data of immunoblotting. Expression of each protein was first normalized by
α-tubulin. Relative expression level under different treatments was then normalized to Con. Data are mean ± SEM. n = 5, *p < 0.05 vs. Con.
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Increased phosphorylation of WNK1 and OSR1 in glioma
cells
WNK1-SPAK/OSR1 signaling pathway is evolutionarily
conserved regulators of ion transport and cell volume by
altering the net phosphorylation state of ion transporters
[13]. Moreover, WNK1 has been identified as an import-
ant kinase involved in development and cancer [14-16].
Mice with homozygous Wnk1 mutation died during em-
bryonic development [15]. In Hela cells, WNK1 is re-
quired for mitosis and abscission [14]. Depletion of
WNK1 with siRNA led to aberrant mitotic spindles, de-
fective abscission and reduced cell survival [14]. WNK1
kinase expression is also found to correlate with inva-
siveness in F11 neural tumor cells [16]. A dramatic de-
crease of WNK1 expression was observed in the cells
with a reduced rate of cell migration and invasion [16].
In the current study, compared to NSC and HA, we
detected increased expression of p-WNK1, t-WNK1 and
p-OSR1 protein in the GBM cell lines. Abundant expres-
sion of p-OSR1 and p-NKCC1 was also revealed in
GBM xenografts and GBM tissue microarray samples.
But, expression of SPAK protein was barely detectable in
GCs, which are consistent with the reports in Hela cells
or other glioma cell lines and glioma specimens [6,17].
p-WNK1 and t-WNK1 expression was not examined in
GBM xenografts or GBM tissue arrays in this study be-
cause no commercial antibodies of WNK1 are specific
for immunostaining. Taken together, these findings sug-
gest that the WNK1/OSR1/NKCC1 signal pathway may
be important in pathogenesis of glioma.WNK1 and OSR1 are the dominant upstream kinases in
regulating NKCC1 in glioma cells
NKCC1 activity is controlled by protein phosphorylation
and dephosphorylation [11]. WNK1/SPAK/OSR1 signal-
ing pathway is the well-studied upstream regulatory
component of NKCC1 [13]. WNK1 is a serine/threonine
protein kinase, which is activated upon hypertonic stress,
low [Cl−]i or isotonic cell shrinkage, and plays an im-
portant role in regulation of SLC12 gene family includ-
ing NKCC [18]. On the other hand, SPAK and OSR1 are
two well-characterized WNK1 substrates [9]. In response
to osmotic stress, WNK1 interacts with SPAK/OSR1 and
phosphorylates them in two sites (Thr233 and Ser373 in
human SPAK, Thr185 and Ser325 in human OSR1 [19].
The phosphorylation triggers activation of SPAK and
OSR1, which in turn stimulates NKCC1 to maintain
intracellular ionic strength and volume [9].
In the current study, we found that knockdown of
WNK1 or OSR1 with siRNA significantly reduced basal
levels of p-NKCC1 protein in GCs. Reduction of either
WNK1 or OSR1 via siRNAs abolished the TMZ-induced
phosphorylation and activation of NKCC1 in GCs. These
data suggest that the WNK1 plays a dominant role in
regulating NKCC1 protein in GCs. We also concluded
that OSR1 is the major intermediate player between
WNK1 and NKCC1 because of the low level of SPAK in
GCs. Furthermore, TMZ treatment at a relatively low
dose is sufficient to stimulate the activities of these two
kinases in glioma cells. Interestingly, among seven recur-
rent GBMs in our TMA analysis, all six biopsies from
the patients treated with TMZ (data not shown) were
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p-OSR1 expression did not receive TMZ treatment prior
to the surgical removal of the tumor (data not shown).
Future studies with increasing sample size of the recur-
rent GBMs with or without TMZ treatment are war-
ranted and will allow us to validate whether TMZ
treatment activates p-OSR1 in GBM.
In addition to WNK1 kinase, Haas et al. reported that
WNK3 kinase is an important regulator of NKCC1
because of its elevated level in high-grade gliomas [6].
While robust expression of WNK1 kinase is also
expressed in normal brain tissues and tumor tissues of
all glioma grades [6]. Compared to normal human
astrocytes, we detected a lower expression level of
WNK3 protein in all three glioma cell lines (Additional
file 1: Figure S4). The discrepancy of these findings on
WNK1 and WNK3 expression may result from hetero-
geneity of the glioma cells.
Of note, GC#22 and GC#99 as well as U87 used in
this study are O6-methylguanine-DNA methyltransferase
(MGMT) negative (unpublished data). Therefore, it war-
rants further studies to validate our findings in MGMT-
positive glioma cell lines.
The WNK1/OSR1/NKCC1 signaling pathway in regulation
of glioma cell migration
The WNK1/OSR1/NKCC1-mediated volume regulation and
glioma cell migration
NKCC1 activity is required in glioma cell migration
[5-7]. In the current study, we found that GC#22 exhib-
ited a slower basal random movement and transwell mi-
gration than GC#99, which is consistent with its low
migration profile in the corresponding GSC xenografts
[20]. We also documented that GC#22 and U87 migra-
tory behaviors were significantly enhanced in the pres-
ence of TMZ. Either inhibition of NKCC1 with BMT or
knockdown of WNK1 and OSR1 with siRNAs abolished
the TMZ-mediated stimulation in GC#22 migration. On
the other hand, there was no change in cell migration in
GC#99 in response to TMZ. But, inhibition of NKCC1
by BMT significantly reduced basal levels of GC#99 mo-
bility and transwell migration. Knockdown of WNK1 by
siRNA also significantly reduced the basal migration of
both GC#99 and GC#22. These findings suggest that the
WNK1/OSR1/NKCC1 signaling pathway plays a role in
GC migration either under basal conditions or in re-
sponse to the TMZ-mediated stress. It has been reported
that TMZ (50 μM) treatment enhanced U87 migration
[21]. We speculate that the possible underlying mecha-
nisms include stimulating the WNK/OSR1/NKCC1
cascade.
Precise regulation of the cell volume is an essential
element for coordinated cell migration. A migrating cell
has to actively govern cell volume regulatory iontransport mechanisms in order to achieve the appropri-
ate morphological alteration [22]. NKCC1 protein could
be involved in GC migration by regulating cell volume.
Others and we have demonstrated that NKCC1 is the
key regulator of cell volume in glioma cells [7,8].
Pharmacological inhibition of NKCC1 or genetically sup-
pression of NKCC1 not only significantly abolishes ac-
tive cell volume regulations in glioma cells [7,8], but also
reduces glioma cell migration in transwell apparatus and
in xenograft tumor tissues [5-7]. Moreover, we have
found that TMZ treatment triggers activation of NKCC1
and in turn induces active cell volume regulatory in GCs
[8]. We reported that inhibition of NKCC1 with its po-
tent inhibitor BMT significantly impaired the replenish-
ment of K+i , Cl
−
i and attenuated RVI in GCs in the
presence of TMZ. In the present study, we further dis-
covered that NKCC1 and its regulatory kinases have an
impact on volume regulation and glioma cell migration.
Knockdown of the NKCC1 upstream kinase WNK1 by
siRNA triggered significant loss of K+i and Cl
−
i and
impaired the NKCC1-mediated RVI in GCs. These
results strongly suggest that TMZ-mediated stimulation
of the WNK1/OSR1/NKCC1 cascade has dual effects on
glioma, it counteracts against loss of K+i , Cl
−
i and AVD in
order to promote GC survival, and it also functions to
maintain focal cell volume regulation and facilitates
glioma migration.
Phosphorylation and interactions of NKCC1 and ezrin in GC
migration
Cytoskeletal rearrangements and adhesion dynamics are
indispensable prerequisites for cell migration [23]. The
ERM proteins are closely related members of the band
4.1 superfamily of proteins [24]. Upon activation, ERM
proteins act as linkers interacting with membrane
proteins and the actin cytoskeleton. This specific func-
tion suggests ERM proteins are essential for many
fundamental cellular processes, including determination
of the cell shape, polarity, surface structure, cell adhe-
sion and motility [24]. ERM proteins, especially ezrin,
have an important role in cancer invasion and metastasis
through regulation of adhesion molecules, participation
in cell signal transduction, and signaling to other cell
membrane channels in the tumor [25,26]. Garzon-
Muvdi and colleagues demonstrated that in glioma cells,
ezrin protein binds to the clusters of positively charged
amino acids in carboxy-terminus domain of NKCC1,
and mutation of the amino acids in these clusters
reduced interaction between NKCC1 and ezrin [5].
In the current study, we concurrently detected an in-
crease in ezrin protein pulled out from the same immuno-
precipitation fractions, in which we observed increased
expression of p-NKCC1 proteins in response to TMZ
stress. Moreover, p-ERM expression was also significantly
Figure 8 Proposed mechanisms underlying TMZ-mediated
regulation of GCs migration. In GBM cells, WNK1 and OSR1 are
the major kinases regulating NKCC1 activity under physiological
condition and in the presence of TMZ treatment. WNK1/OSR1
kinases function in stimulation of NKCC1 activity to maintain K+i and
Cl−i and cell volume homeostasis in the leading edge to promote
cell migration. In addition, WNK1 may increase interactions between
NKCC1 and ezrin to stimulate cell cytoskeletal rearrangements and
further promote migration. Taken together, our findings suggest that
targeting the WNK1/OSR1/NKCC1 pathway may synergistically
reduce GBM cancer cell survival and migration in conjunction with
TMZ treatment.
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that phosphorylation of NKCC1 and ERM proteins may
enhance their interactions. Several studies suggest that
ERM proteins are phosphorylated and activated by the
small GTPase Rho [27,28] or Akt kinase [28]. Interest-
ingly, Akt has been shown to be activated by TMZ treat-
ment in several types of cancer cells, such as pituitary
adenoma [29], breast carcinoma [30], and metastatic mel-
anoma [31]. Moreover, WNK1 has been suggested as a
substrate of Akt kinase [9]. WNK1 is involved in regula-
tion of Nogo-induced RhoA activation in PC12 neuronal
cells. Knockdown of WNK1 by siRNA dramatically de-
creases the elevation of RhoA activity by Nogo treatment
[32]. Therefore, it is possible that TMZ treatment may
concurrently stimulate both phosphorylation of NKCC1
and ERM complex following activation of the WNK1 and
Akt-mediated cascades, which enhances interactions be-
tween NKCC1 and ERM proteins during GC migration.
It is noteworthy that three different glioma cell lines
responded differently to BMT treatment in our study.
There is an apparent correlation between increased sen-
sitivity to BMT treatment and higher basal cellular mo-
tility in these cell lines. GC#99, with aggressive profile
and higher basal motility [20], demonstrated a more pro-
found reduction in cell migration upon BMT treatment.
However, when we compared whether p-NKCC1 and t-
NKCC1 are differentially expressed among these cell
lines, no significant differences were detected (Figure 1A
and B). Studies have shown that an increase in transloca-
tion of NKCC1 protein from intracellular stores to the
cytoplasmic membrane surface affects its activity in
chondrocyte, parietal, and chief cells [33,34]. Thus, there
might be differential NKCC1 expression on the cytoplas-
mic membrane in GC#99 versus other two cell lines,
which may cause the difference of BMT sensitivities.
Moreover, the expression level of t-WNK1 is significantly
higher in GC#99, compared to GC#22 (127.1 ± 7.7%, p <
0.05) and U87 (173.9 ± 10.0%, p < 0.05). Whether the ele-
vated kinase expression plays a role in NKCC1 protein
trafficking, it warrants further investigation.
Conclusion
In summary as described in Figure 8, we concluded that
WNK1 and OSR1 are the important upstream kinases in
regulating NKCC1 activity in GBM cells in response to
physiological (low Cl−i , cell shrinkage) or non-physiological
stress (TMZ-mediated stress). WNK1/OSR1 kinases func-
tion in stimulation of NKCC1 activity to maintain intracel-
lular K+ and Cl− and cell volume homeostasis, which is
important for glioma migration. In addition, phosphoryl-
ation of NKCC1 enhances its interactions with ezrin to
stimulate cell cytoskeletal rearrangements and further pro-
motes cell migration. Taken together, these novel findings
suggest that combination of TMZ-mediated chemotherapywith inhibition of the WNK1/OSR1/NKCC1 signaling
pathway presents a new strategy for improving glioma
treatment.
Materials and methods
Materials
Gramicidin, nigericin, tributyltin, valinomcycin, TMZ, and
BMT were purchased from Sigma Chemicals (St. Louis,
MO). Dulbecco’s Modified Eagle Medium (DMEM), accu-
tase, goat anti-IgG secondary antibodies Alexa Fluor® 488
and 546, PBFI-AM, calcein-AM, MQAE, and pluronic acid
were obtained from Invitrogen (Carlsbad, CA). Elite Vector
Stain ABC System and 3-3′-diaminobenzidine (DAB) were
from Vector Laboratories (Burlingame, CA). Rabbit
anti-WNK1 (t-WNK1) (N-20, #sc-20468) was from Santa
Cruz Biotechnology (Dallas, TX). Rabbit anti-phospho-
WNK1 (p-WNK1) (T60, #AF4720) was from R&D Systems
(Minneapolis, MN). Sheep anti-WNK3 (S156C) was
developed previously described [35]. Mouse anti-NKCC
(T4) antibody was from Developmental Studies Hybridoma
Bank (Iowa City, IA). Mouse anti-α-tubulin (#2125), rabbit
anti-ezrin (#3145), rabbit anti-ezrin/radixin/moesin (ERM)
(#3142) and rabbit anti-phosphorylated-ERM (#3149)
antibodies were from Cell Signaling (Beverly, MA). Rabbit
anti-phosphorylated-NKCC1 (p-NKCC1) antibody (R5)
was a kind gift from Dr. Biff Forbush (Yale University).
Sheep anti-phosphorylated-NKCC1 recognizing the same
residues (Thr212 and Thr 217) as R5 was developed as
previously described [35]. Rabbit anti-SPAK/OSR1
(t-SPAK/t-OSR1) and rabbit anti-phosphorylated-SPAK
(Ser373)/OSR1 (Ser325) (p-SPAK/p-OSR1) were developed
as described before [36,37].
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All studies involving human tissues were performed with
approval from the University of Wisconsin-Madison and
University of Pittsburgh Institutional Review Board with
informed consent obtained from patients.
Primary glioma cell lines (GC#22 and GC#99) were
established as described before [38]. U87 cell line was
purchased from American Type Culture Collection. All
glioma cell lines were grown in adherent cultures and
maintained in DMEM supplemented with 10% FBS. Cul-
tures were passaged approximately every 4 days with
fresh medium at a density of 106 cells/75 cm2 in a cul-
ture flask. Passages of 16–40 were used in this study.
Human cortex fetal neural stem cells (NSCs) and hu-
man astrocytes (a kind gift from Dr. Clive Svendsen)
were used as a control and maintained as previously de-
scribed [39].Immunofluorescence and immunohistochemistry
Immunofluorescence staining was conducted on xeno-
grafts of NOD-SCID mouse brains implanted with glioma
as described before [38]. Briefly, 10 μm formalin-fixed,
paraffin-embedded tissue sections were mounted on
microscope slides. Tissue sections were deparaffinized and
rehydrated to water, and microwaved in antigen unmask-
ing solutions (Vector laboratories) for 20 min to retrieve
epitopes. Sections were then incubated with a blocking so-
lution (0.3% Triton X-100/5% goat serum) for 60 min at
room temperature (RT) and with primary antibodies
(sheep anti-p-NKCC1 1:100, mouse anti-t-NKCC1 1:100)
overnight at 4°C. After rinsing in phosphate buffered
saline (PBS) for 15 min, tissue sections were incubated
with respective secondary antibodies conjugated to Alexa
Fluor® 488 or Alexa Fluor® 546 (1:200 dilution) for 2 h at
RT. Sections were then rinsed and incubated with To-pro-
3 iodide (1:1000 in antibody diluting solution) for 15 min
at RT and mounted with Vectashield mounting medium.
Fluorescence images were captured with a Leica DMIRE2
inverted confocal laser-scanning microscope under the
40× oil immersion objective lens. Samples were excited at
488 nm (argon/krypton), 543 nm, and 633 nm. The emis-
sion fluorescence was recorded at 512–548 nm, 585–
650 nm, and 650–750 nm, respectively.
For immunohistochemistry study, sections were blocked
for endogenous peroxidase and biotin before the applica-
tion of the primary antibody. Incubation of primary anti-
bodies (rabbit-anti-p-SPAK/OSR1 1:50, mouse anti-t-OSR1
1:50) was conducted overnight at 4°C. Incubation of sec-
ondary antibodies was applied for 2 h at RT. Subsequent
immunodetection was conducted using the Elite Vector
Stain ABC System. Color visualization was conducted using
DAB as the chromagen substrate. Tissues were counter-
stained with hematoxylin to visualize cellular morphology.Images were acquired with a Nikon TE-2000 brightfield
microscope.
GBM tissue microarray
A tissue microarray from 205 GBM patients diagnosed
between 1999 and 2009 was created from the UW De-
partment of Pathology and Laboratory Medicine archives
as described [20]. Out of 205 patients, 138 patients had
a recorded value for overall survival and a preserved tis-
sue punch. Diagnosis and tissue punch location were de-
fined by neuropathology prior to incorporation into
microarray [20]. Rabbit anti-p-SPAK/OSR1 (1:50) was
used to label the tissue microarray. Each punch was sub-
jectively scored for negative (score 0), mild (score 1),
moderate (score 2) and strong (score 3) of p-SPAK/
OSR1 expression by light microscopic visualization of
intensity of cytoplasmic DAB. Nuclear or fibrillary label-
ing was not scored as positive. In cases of multiple
punches/cores for one patient tumor sample, the score
given represented the most frequent expression level.
Cell motility measurement with time-lapse imaging
Glioma cells on 35 mm cell culture dishes were placed
in a stage top incubator at 37°C with 5% CO2 + 95% air
(TIZ model, Tokai Hit; Shizuoka-ken, Japan). Motility of
cells was monitored under 10× objective lens with a
time-lapse video microscope system (the Nikon TiE 300
inverted epifluorescence microscope) and MetaMorph
software (Molecular Devices; Sunnyvale, CA, USA).
Time-lapse DIC images were acquired in 5-min intervals
for 5 h either under control conditions (DMEM supple-
mented with 10% FBS) or in the presence of 10 μM
BMT, 100 μM TMZ, or 100 μM TMZ plus 10 μM BMT.
Images were analyzed by ImageJ software (National In-
stitute of Health, USA) and cell tracking was performed
using the Manual Tracking plugin. Total distance trav-
eled was determined by tracking the movement of the
cell gravity center, and its coordinates were used to cal-
culate the distances. The slope of the curve was obtained
as averaged speed.
Serum-induced microchemotaxis assay
Transwell membrane cell culture inserts (8.0 μm pore
size, Becton Dickinson) were coated with 0.5 μg/ml
poly-d-lysine overnight at RT and washed in PBS for
5 min for 3 times. Dissociated GCs (4 × 104 cells) in
100 μl serum-free DMEM with different treatment regi-
mens (control medium, 10 μM BMT, 100 μM TMZ, or
100 μM TMZ plus 10 μM BMT) were seeded on the top
of the membrane insert, and the lower wells contained
700 μL DMEM plus 10% FBS. After incubation for 5 h
in the cell culture incubator at 37°C, cells were fixed
with 4% paraformaldehyde (PFA) and non-migrated cells
on the inserts were wiped off with cotton q-tips. The
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DAPI staining (2 μg/mL in PBS) for 15 min at RT. The
membranes were removed and inertly mounted on
microscope slides. Slides were excited at 358 nm with a
xenon lamp and the emission fluorescence at 461 nm re-
corded with a Princeton Instruments MicroMax CCD
camera attached to the Nikon TiE microscope using the
MetaMorph software. Images of 5 random fields were
captured under the 40× objective lens. Migrated cells in
all 5 fields were averaged to give a mean cell count for
each experiment.
Intracellular Cl− concentration ([Cl−]i) measurement
The fluorescent dye MQAE was used to determine [Cl−]i
as described by Rocha-Gonzalez [40] with some modifi-
cations [8]. Cells were incubated with 5 mM MQAE for
1–2 h (37°C) in a HEPES buffered isotonic solution. The
HEPES buffered isotonic solution contained (in mM,
pH 7.4): 100 NaCl, 5.4 KCl, 1.3 CaCl2, 0.8 MgSO4, 20
HEPES, 5.5 glucose, 0.4 NaHC03, and 70 sucrose with
310 mOsm determined with an osmometer (Advanced
Instruments, Norwood, MA). The coverslip was placed
in the heated imaging chamber for 30 min before im-
aging. Using the Nikon TiE inverted epifluorescence
microscope and the 40× oil immersion objective lens,
cells were excited every 60 sec at 340 and emission
fluorescence at 460 nm recorded. Images were collected
and analyzed with the MetaFluor image-processing soft-
ware. At the end of each experiment, the MQAE flo-
rescence was calibrated under a steady state condition
when [Cl−]o and [Cl
−]i were considered equal by expos-
ing cells to a series of calibration solutions containing
10 μM tributylin and 5 μM nigericin (Rocha-Gonzalez,
Mao, and Alvarez-Leefmans 169–84). The series of Cl−
calibration solutions contained (in mM): 1.27 Ca(OH)2,
0.8 MgSO4, 5 HEPES, 5.5 glucose, 120 K
+, and variable
Cl− and NO3
−. In these solutions, Cl− was varied from 0
to 60 mM keeping the sum of Cl− and NO3
− equal to
120 mM. KSCN (150 mM) was used to quench the
MQAE fluorescence, which was taken as background
fluorescence. [Cl−]i was determined from the MQAE
fluorescence (drift-corrected, background-corrected)
using the following equation: [Cl−]i = [(Fo/Ft) − 1)]/Ksv,
where Fo was the fluorescence in 0 mM [Cl
−]o, Ft was
the fluorescence at any given time point, and Ksv was
the slope of the linear fit of MQAE fluorescence vs. the
[Cl−]o of the standards. A Ksv of 13.4 ± 1.5 M
−1 was cal-
culated in our study [8], a value similar to that reported
by others [40].
Intracellular K+ concentration ([K+]i) measurement
[K+]i was determined by a modified method as described
by Kiedrowski [41]. Briefly, cells were incubated with
5 μM PBFI-AM plus 0.02% pluronic acid at 37°C for90 min. The coverslips were placed in the heated im-
aging chamber at 37°C. Cells were rinsed and images
collected using the Nikon TiE inverted epifluorescence
microscope equipped with the 40× oil immersion object-
ive lens. Cells were excited every 20 sec at 340 and
380 nm and the emission fluorescence was recorded at
510 nm. Images were analyzed with the MetaFluor
image-processing software. At the end of each experi-
ment, a calibration was performed by exposing cells to
standards of varying K+ concentrations plus gramicidin
and valinomcycin (10 μM each). K+ standards contained
30 mM NaCl, 20 mM HEPES, and 1 mM MgCl2, with
varied K+ from 20 to 120 mM by substituting K+-gluco-
nate and LiCl such that the sum of K+ and Li+ was
100 mM.
RNA interference knockdown of WNK1 or OSR1
Knockdown of WNK1 or OSR1 protein expression was
induced by small interfering RNA (siRNA). The scram-
ble siRNA (Silencer® Negative Control No. 1 siRNA,
Cat. No. AM4635) and siRNAs targeting human WNK1
(ID: s35235) and OSR1 (ID: s19302) were purchased
from Invitrogen. The sequences of WNK1 siRNAs are:
sense 5′-CAAUGSGUCAGAUAUACGAAtt-3′; antisense
5′-UUCGAUAUCUGACUCAUUGtc-3′; OSR1 siRNA:
sense 5′-GAACCUCAGUCAAAUCGAUtt-3′; antisense
5′-AUCGAUUUGACUGAGGUUCtt-3′. Dissociated GCs
were seeded in 6-well plates (105 cells/well/2 ml) in
DMEM plus 10% FBS at 24 h prior to transfection. Lipo-
fectamine RNAiMAX/siRNA complexes were prepared by
adding siRNA (15 nM as a final concentration) and 5 μl of
Lipofectamine RANiMAX (Invitrogen, Carlsbad, CA) in
500 μL serum-free optiMEM. Complexes were allowed to
form at RT for 10 min and added to each well in the 6-
well plate. The cells were incubated at 37°C and subjected
to experiments 48 h after transfection.
Immunoblotting assay
Cells were washed with ice-cold PBS that contained 2 mM
EDTA and protease inhibitors as described before [42].
Cells were lysed by sonication on ice. Protein content of
the cellular lysate was determined with BCA Protein Assay
Kit (Pierce, Rockford, IL). Samples (30 μg lysate protein)
were denatured in SDS reducing buffer (1:2 vol/vol) and
heated at 90°C for 5 min, and then electrophoretically sep-
arated on 8-10% SDS gels. After transferring to PVDF
membranes, the blots were blocked in 7.5% nonfat dry
milk with Tris buffered saline for 1 h at RT and incubated
with a primary antibody at 4°C overnight. The blots were
probed with monoclonal T4 antibody against total NKCC1
(1:2000), polyclonal antibody (R5) against a diphospho-
peptide containing T184 and T189 of shark NKCC1 (p-
NKCC; 1:1000), rabbit anti-t-WNK1 (1:500), rabbit
anti-p-WNK1 (1:1000), rabbit anti t-SPAK/OSR1 (1:200)
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incubated with horseradish peroxidase-conjugated sec-
ondary IgG for 1 h at RT. Bound antibody was visualized
with an enhanced chemiluminescence assay (Amersham,
Piscataway, NJ).
Immunoprecipitation was conducted to examine inter-
actions between NKCC1 and ezrin proteins using the
Pierce® Classic IP Kit (ThermoScientific, Rockford, IL,
USA). Cellular lysate samples (0.2 mg protein) were incu-
bated with 2 mg of mouse anti-t-NKCC1 antibody at 4°C
overnight. Immunocomplexes were mixed with 20 μL pro-
tein A/G beads (50% slurry) in a Pierce spin column and
incubated for 2 h. The immunocomplexes were washed
and dissociated from beads with the Laemmli sample buf-
fer and heated at 95°C for 10 min. The resolved proteins
and prestained molecular mass markers were separated on
7.5% SDS-PAGE. The blots were probed for t-ezrin, p-
NKCC1, and t-NKCC1 (for equal total protein input con-
trol). Densitometric measurement of each protein band
was performed using the Gel Analysis Tool in Image J.
Statistical analysis
The results are expressed as the mean ± SEM. Compari-
sons between groups were made by Student’s t-test or one-
way ANOVA using the Bonferroni post-hoc test in the case
of multiple comparisons (SigmaStat, Systat Software, Point
Richmond, CA, USA). p < 0.05 was considered statistically
significant. n values represent the number of independent
cultures or tissue samples.
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Additional file 1: Figure S1. Visualization of expression of SPAK in GCs
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OSR1/NKCC1 signaling pathway does not change in the presence of
TMZ. Figure S4. Low expression of WNK3 in glioma cell lines.
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